Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Gabriella McCarty

NP-C

Gabriella McCarty is a gastroenterology/hepatology nurse practitioner. She obtained her masters and nurse practitioner degree at Case Western Reserve University in 2004. She has been practicing in this field for 26 years. She serves as faculty for Gastroenterology/ Hepatology Advanced Practice Providers (GHAPP) and is an American College of Gastroenterology (ACG) committee member, serving on the education subcommittee. She will be completing her doctorate of nursing in May 2025. She loves all aspects of GI / Hepatology, education and nursing.

play

Alison Moe

PA-C

Alison S. Moe, MS, PA-C, is a board-certified physician assistant specializing in gastroenterology at United Digestive's Braselton office in Hoschton, Georgia. She earned her Master of Science in Medical Education from Seton Hall University and a Bachelor of Arts in Physical Anthropology from the State University of New York at Stony Brook. Alison is fluent in Spanish and has a special interest in treating irritable bowel syndrome and liver disease. With almost two decades of experience as a Physician Assistant, Alison has developed a strong foundation in both clinical practice and research, particularly in the fields of gastroenterology and hepatology. Alison's dedication to patient care includes extensive clinical hours, allowing her to cultivate deep relationships with patients as well as national experts caring for individuals, especially those suffering from inflammatory bowel disease (IBD) and advanced liver disease. Alison's commitment to advancing the understanding and treatment of these conditions drives my clinical practice and ongoing research efforts, aiming to provide the highest standard of care for my patients.

play

Christie Morrison

AGACNP-BC

Christie Morrison is a Board Certified Adult Advanced Practice Nurse and Lead APP at Oshi Health, a digital digestive health practice and IBD APP at Texas Digestive Disease Consultants in San Antonio, Texas. She strives to improve the lives of patients with chronic gastrointestinal conditions through a multidisciplinary approach. She has worked in various roles as a GI advanced practice provider, including inpatient, outpatient clinic, and telehealth since 2015. Mrs. Morrison is currently an active member of the American College of Gastroenterology where she is serving on the Editorial Board. She is also a member of several GI societies, including TSGE, AGA, ASGE, and GHAPP. Christie was recently honored with the ACG APP Clinical Excellence Award for community practice. She collaborates with industry partners and GI colleagues to enhance education and engagement for APPs working in Gastroenterology. She strives to improve the quality of life and better patient outcomes in all chronic GI conditions and believes that providing resources to her peers through education can help her achieve this goal.

play

Jill Olmstead

DNP, ANP-BC

Jill Olmstead, DNP, ANP-BC, is a gastroenterology nurse practitioner with Providence St. Jude Heritage Medical Group in Fullerton, California. She specializes in diagnosing and managing gastrointestinal disorders, offering compassionate, evidence-based care to improve patient outcomes.

play

Oyin Penny

MSN, FNP

Oyin Penny is a dedicated and experienced Nurse practitioner in Hepatology and Gastroenterology with a passion for providing comprehensive care to patients with various gastrointestinal disorders and liver disease. Oyin has 13+ years of clinical experience. She has an expertise in managing patients in conditions such as Steatotic liver disease (metabolic liver disease), chronic liver disease, hepatitis (acute or chronic), inflammatory bowel disease and functional GI disorders in both inpatient and outpatient settings. She actively collaborates with multidisciplinary teams to ensure her patients receive the best quality care. Oyin is committed to a patient-centered care, with emphasis on education, disease prevention, and lifestyle modifications to improve health outcomes. In addition to clinical experience, Oyin is passionate about patient advocacy and mentorship. She is currently a Mentor for APPs for the ACG and also initiated and leads the KC Gut club for APPs in GI and Hepatology in the Kansas City area.

play

Emily Przybyl

PA-C

Emily Przybyl is a physician assistant who specializes in gastroenterology and hepatology at Erie County Medical Center in Buffalo, NY. She earned her Bachelor of Science in Health Sciences and Master of Science in Physician Assistant Studies at Daemen University in Amherst, NY. She has over 5 years experience in her field and has a special interest in treating patients with MASLD/MASH.

play

Lisa Richards

MSN, FNP-BC, AF-AASLD

Lisa Richards is a highly experienced Family Nurse Practitioner at the University of California, San Diego Health System. She earned her Bachelor of Science and Master of Science degrees in Nursing, graduating magna cum laude, from the University of San Diego. With over 22 years of experience in Hepatology, Lisa has developed specialized expertise in MASLD (Metabolic Associated Steatotic Liver Disease) and its related research. She currently serves as the Assistant Director of Clinical Operations at the MASLD Research Center, where she plays a pivotal role in advancing the field. A dedicated member of the American Association for the Study of Liver Diseases (AASLD), Lisa has been honored with the prestigious title of Associate Fellow, recognizing her excellence and leadership in Hepatology. In addition to her clinical and research work, Lisa is an active speaker and thought leader in her field. She has presented at esteemed events such as the AASLD Annual Meeting, Global Hepatology and Advanced Practice Providers (GHAPPP), and various local and regional conferences, sharing her deep knowledge and insights into Hepatology. Known for her leadership and expertise, Lisa Richards is widely regarded as a key figure in advancing MASLD research and Hepatology care.

play

Jordan Mayberry

MPAS, PA-C

Jordan Mayberry completed her master’s in physician assistant studies at UT Southwestern School of Health Professions in 2012. She completed the AASLD NP/PA Fellowship in 2013. She has been practicing hepatology in a large academic setting for over 12 years. She enjoys mentoring new APPs and serves as a lecturer and preceptor for the UT Southwestern Physician Assistant program and was awarded Outstanding Educator Award in 2023. She has given plenary talks at The Liver Meeting, Digestive Disease Week and GHAPP national and regional meetings. She currently serves at the vice chair for the Associates committee for AASLD.

play

Carla Molliner

PA-C

Carla M. Molliner, PA-C, is a seasoned physician assistant specializing in hepatology at the University of Miami Health System. With over two decades of clinical experience, she provides expert care in liver diseases and transplant hepatology. She is fluent in both English and Spanish, enhancing her ability to serve a diverse patient population.​ Carla Molliner earned her master's degree from Nova Southeastern University and completed a fellowship in hepatology at the University of Miami. She is board-certified by the National Commission on Certification of Physician Assistants. Currently, she serves as the APP Team Manager (H) at the University of Miami, where she leads advanced practice providers in hepatology. ​ In addition to her clinical duties, Carla Molliner actively participates in academic and educational initiatives. She was a featured speaker at the 2024 Advances in Hepatobiliary Diseases conference, where she presented on age-appropriate health care maintenance beyond liver disease.

play

Ann Moore

NP

Ann Moore is a hepatology nurse practitioner and VP of Clinical Services at Arizona Liver Health. She has over 30 years of liver disease and liver transplant management experience and is recognized nationally for her liver disease expertise. In addition to her clinical practice, she serves as Principal Investigator for multiple clinical trials in MASH and other liver diseases. Throughout her career, Ann has worked to expand access to liver disease care throughout the state of Arizona, running numerous outreach clinics in rural locations.

April Morris

FNP

Mrs. April Morris received a bachelor of science in biology and nursing from Virginia Commonwealth University (VCU) in Richmond, Virginia. She went on to complete a master’s degree in nursing at VCU and became a board-certified family nurse practitioner in 2006. Initially, she worked in hepatology at VCU Medical Center for many years focusing on treating those patients with chronic hepatitis C. She then worked in a community hospital-based setting at the Liver Institute of Virginia in Newport News, VA and Richmond, VA for several years as the senior nurse practitioner. In this role, she gained extensive experience evaluating and managing patients with various acute and chronic liver diseases and conditions, including complications related to cirrhosis and hepatocellular carcinoma (HCC). She was also a sub-investigator for many liver-related clinical trials including studies conducted to develop better oral medications for chronic hepatitis C, NASH and PBC. Currently, she works full-time in the GI/Hepatology department at Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, VA. In this role, she is primarily working to help develop a metabolic liver clinic to benefit those patients with NASH. Mrs. Morris is a member of the American Academy of Nurse Practitioners, American Association for the Study of Liver Diseases, American College of Gastroenterology, Virginia Council of Nurse Practitioners and an executive committee member and advisor for Chronic Liver Disease Foundation (CLDF).

play

Janet Gripshover

DNP, MBA

Janet Gripshover, DNP, MBA, AF-AASLD, is a highly experienced Family Nurse Practitioner and Nurse Manager for Cedars-Sinai’s Liver Transplant Program in Los Angeles. With over 15 years of clinical and leadership expertise in hepatology, Dr. Gripshover is recognized for her commitment to advancing the role of Advanced Practice Providers (APPs) in liver care. She has led numerous initiatives to foster APP education and collaboration, including founding the APP HCV Consortium in Baltimore, MD, and creating the GI APP Grand Rounds series at Geisinger Wyoming Valley in Wilkes-Barre, PA. In addition to speaking at national conferences, Dr. Gripshover has developed and delivered a wide range of educational and professional development seminars for non-physician providers across the country. An advocate for patient-centered innovation, she also founded and moderated the first hospital-sponsored Facebook support group for liver transplant recipients — a project that earned her the New Media Award for Healthcare from the Baltimore Business Journal and national recognition. Dr. Gripshover is an active member of the American Association for the Study of Liver Diseases (AASLD), where she has served on the Hepatology Associates Committee and the Women’s Initiatives Committee, helping launch the AASLD Women’s Leadership Program. She currently serves as Vice Chair of AASLD’s Hepatology Associates Special Interest Group and is also a member of the Hepatology Associates Committee for the American College of Gastroenterology (ACG).

play

Milly Ng

FNP, MPH

Miu Lai "Milly" Ng FNP-BC, MPH is a dedicated Nurse Practitioner specializing in hepatology at Tufts Medical Center, with 8 years of experience in managing patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), including the lean MASH population. Passionate about improving liver health within the Asian population, Miu Lai is actively engaged in community outreach and education. Their clinical expertise includes the use of GLP-1 receptor agonists and liver-targeted medications to optimize treatment outcomes. In addition to clinical practice, Miu Lai serves as a consultant for Pharmaceuticals and contributes expertise to multiple advisory boards and podcasts, advocating for advancements in hepatology care.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Erin Parkinson

MS, APRN, FNP-C

Erin Parkinson has been a board-certified family nurse practitioner since 2007 and has been practicing in Transplant and Non-transplant Hepatology with the Tampa General Medical Group since 2011. She is the Lead Advanced Practice Provider for the Hepatology program. She has presented at national and regional meetings and is the author of multiple abstracts and poster presentations. She serves as a sub investigator for multiple clinical trials within hepatology and conducts her own research surrounding APP led practice initiatives and hepatitis C. She is a member of the AASLD annual meeting education committee and was a mentor for the ELAPP program with AASLD. She resides in St. Petersburg Florida with her husband and two sons.

play

Christina Hanson

FNP-C

Christina Hanson is a nurse practitioner in Gastroenterology and Hepatology at South Denver GI, with nearly 20 years of clinical practice. She is a course director and board of trustee for GHAPP. An active researcher with extensive leadership and teaching experience, she is a champion of evidence-based practice, data-driven care delivery, interdisciplinary collaboration, and quality patient care. Christina is committed to amplifying professional development, growth, and contributions of advanced practice.

play

Summer Collier

MSN, FNP-BC

Summer Collier is a nurse practitioner with advanced expertise in hepatology and a strong commitment to evidence-based, multidisciplinary care. At UC San Diego Health, she provides comprehensive management for patients with chronic liver disease, including viral hepatitis, autoimmune hepatitis, alcohol-associated liver disease, and metabolic dysfunction–associated steatotic liver disease (MASLD). Collier is actively engaged in clinical research and has participated in multidisciplinary studies on liver fibrosis, steatosis, and treatment protocols for hepatitis C and alcohol use disorder. Her scholarly work focuses on improving transitions of care for patients with cirrhosis and expanding access to pharmacologic treatments for patients with alcohol use disorder. A recognized leader in the field, Collier has presented at national conferences including The Liver Meeting (AASLD), Digestive Disease Week (DDW), and GHAPP, speaking on topics such as cirrhosis care, hepatology red flags, and advanced practice provider leadership. She previously served as Chair of the Advanced Practice Council at UC San Diego Health, driving initiatives that elevated APP visibility and impact within the organization. Before joining UC San Diego Health, she was a family nurse practitioner and HIV specialist with Family Health Centers of San Diego. She also has prior experience as a registered nurse. Collier completed a Master of Science in Nursing degree from University of San Diego and will complete the Doctor of Nursing Practice degree from University of California, Los Angeles in June 2025. She is certified by the American Nurses Credentialing Center.

play

Allysa Saggese

NP

Allysa Saggese is a graduate of Columbia University School of Nursing with a Master's Degree in Nursing. She is board certified with the ANCC as an Adult-Gerontology Primary Care Nurse Practitioner. She has worked in Hepatology, Liver Transplantation and Hepatology Research at Weill Cornell Medicine since 2018. Her main interests include Steatotic Liver Disease, Primary Biliary Cholangitis and cirrhotic liver disease, as well as the spectrum of research within hepatology.

play

Patrick Horne

ARNP

Patrick M. Horne, MSN, APRN-BC, FNP, AF-AASLD is the Assistant Director of Clinical Hepatology Research and Clinical Programs Coordinator at the University of Florida’s Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition. He holds bachelor's and master's degrees from the University of Florida College of Nursing. His research focuses on hepatology clinical trials, including viral hepatitis, MASH, autoimmune hepatitis, cholestatic liver disease, and HCC. He has published extensively in clinical hepatology and has presented at major conferences such as AASLD, AGA NP/PA, and GHAPP.

play

Valerie Shin

NP

Valerie Shin earned her Bachelor of Science in Nursing from New York University. After earning her degree, she advanced her nursing career with the Cleveland Clinic in Cleveland, Ohio, and the Veterans Affairs Medical Center in West Los Angeles, California. Valerie furthered her career by completing the Acute Care Nurse Practitioner program at the University of California, Los Angeles, where she obtained a Master’s degree. During her clinical rotation, she had the privilege of being mentored at the liver clinic, where she developed a strong interest in hepatology and the management of liver diseases. This experience led her to her current role as a Hepatology Nurse Practitioner at the Pfleger Liver Institute at UCLA Health, where she continues to specialize in liver disease care. In addition to providing exceptional patient care, Valerie Shin has a strong passion for education, both in teaching future APPs and empowering her patients. She enjoys educating her NP students in her clinic and was honored with the opportunity to lecture NP students at UCLA School of Nursing on the topic of liver cirrhosis and its complications. Valerie also contributes to the annual UCLA Patient Seminar for Liver Diseases, where she provides essential patient education. Furthermore, she is actively involved in the GHAPP meetings, demonstrating her ongoing commitment to advancing both the education of current and future APPs and the care of liver disease patients.

MASLD/MASH Learning Center

Latest News & Blogs

Analysis and verification of potential ferroptosis-related diagnostic markers in the early stage of metabolic dysfunction-associated steatohepatitis

August 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is currently the fastest-growing cause of liver-related deaths. Intervention in the early stage of MASH will effectively reverse the condition and avoid huge health and economic burdens. To date, our understanding of MASH remains quite limited. Its pathogenesis remains not fully understood, and effective diagnostic and therapeutic tools are lacking. Although ferroptosis is closely related to MASH and seen as a promising target, its exact...

Read More arrow

Sex and gender differences in metabolic dysfunction-associated liver disease

August 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is the most prevalent cause for chronic liver disease globally, with a rising incidence of metabolic-associated steatohepatitis (MASH) and its complications. This review examines the critical role of sex and gender in MASLD/MASH prevalence, progression and clinical outcomes. Biological sex affects MASLD significantly with males exhibiting higher rates of downstream...

Read More arrow

Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

August 2025

Macrophages expressing Trem2 play a pivotal role in promoting non-alcoholic steatohepatitis (NASH; also known as metabolic dysfunction-associated steatohepatitis, MASH) progression to hepatocellular carcinoma (HCC). Despite the widespread clinical use of anti-PD1 immune checkpoint blockade, its therapeutic efficacy in NASH-driven HCC remains suboptimal. This study investigates the mechanisms by which NAM Trem2 influences the response of NASH-driven HCC to immunotherapy. Clinical analysis...

Read More arrow

Association of Clinical, Psychosocial, and Social Determinants of Health Factors and Liver Transplantation and Waitlist Removal for MASH

August 2025

CONCLUSIONS: Rates of LT and LT waitlist removal did not significantly differ by MASH etiology, though patients with MASH were significantly more likely to die on the LT waitlist. There continue to be SDOH factors associated with rates of LT, with male sex and employment independently conferring higher odds of access to LT.

Read More arrow

Laparoscopic Low Anterior Resection for Rectal Cancer in a Patient With Rectal Varices Secondary to Metabolic Dysfunction-Associated Steatohepatitis-Related Cirrhosis: A Case Report

August 2025

Rectal varices (RVs) are a known complication of portal hypertension in patients with liver cirrhosis; however, the coexistence of rectal cancer and RVs in the setting of metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis is rare. Herein, we report the successful laparoscopic management of rectal cancer complicated by RVs in an 80-year-old woman with Child-Pugh class A cirrhosis. A colonoscopy revealed rectal adenocarcinoma with surrounding varices. Given the patient's...

Read More arrow

Repeatability and reproducibility of artificial imaging based digital pathology for the evaluation of liver fibrosis

August 2025

CONCLUSION: The qFibrosis system has good repeatability and reproducibility for fibrosis staging. It can provide an accurate reference for pathologists to stage liver fibrosis more objectively.

Read More arrow

Developing risk stratification strategies and biomarkers for recurrent hepatocellular carcinoma

July 2025

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with high rates of post-resection recurrence posing significant clinical challenges. Early recurrence is largely driven by aggressive tumor biology, while late recurrence reflects de novo carcinogenesis in a cirrhotic liver. Traditional clinical and pathological predictors are insufficient for accurately identifying high-risk patients. Emerging translational advances including genomic, transcriptomic, proteomic,...

Read More arrow

MASLD: insights on the role of folate in hepatic lipid metabolism

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is also known as fatty liver disease associated with non-alcoholic fatty liver disease (NAFLD), which is a spectrum of chronic liver diseases characterized by steatosis, inflammation, fibrosis and liver injury. The incidence and prevalence of MASLD is increasing rapidly worldwide. It is a multifactorial disease and there is no single drug approved for its treatment. The liver is the main organ that stores and metabolizes the B9...

Read More arrow

ACLY inhibition promotes tumour immunity and suppresses liver cancer

July 2025

Immunosuppressive tumour microenvironments are common in cancers such as metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC) (MASH-HCC)^(1-3). Although immune cell metabolism influences effector function, the effect of tumour metabolism on immunogenicity is less understood⁴. ATP citrate lyase (ACLY) links substrate availability and mitochondrial metabolism with lipid biosynthesis and gene regulation^(5-7). Although ACLY inhibition shows antiproliferative...

Read More arrow

Hepatocyte KCTD17-mediated SERPINA3 inhibition determines liver fibrosis in metabolic dysfunction-associated steatohepatitis

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of chronic liver disease. Available therapies show inconsistent results on fibrosis, probably due to heterogeneity in disease trajectory or incomplete understanding of molecular determinants. Here we identified increased KCTD17 levels in patients with MASH, and in dietary rodent models of MASH-such as those fed a diet high in palmitate, sucrose and cholesterol coupled with fructose-containing drinking water or a...

Read More arrow

Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials

July 2025

CONCLUSIONS: GLP-1RAs are a promising treatment option for MASLD or MASH. Further research is needed to evaluate the long-term effects of GLP-1RAs on liver-related clinical events.

Read More arrow

Plain language summary about GLP-1 treatments in people with metabolic dysfunction-associated steatotic liver disease

July 2025

No abstract

Read More arrow

Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is now recognized as the most prevalent chronic liver disease worldwide, driven by the rise in obesity, type 2 diabetes, and metabolic syndrome. The evolving nomenclature and understanding of MASLD necessitate updated insights into its pathophysiology, diagnostics, and internal medicine management. A comprehensive literature review was conducted using PubMed, Scopus,...

Read More arrow

Evolving etiologies of liver transplantation: a trend analysis from 2020 to 2024 at the main center of Iran

July 2025

CONCLUSION: The significant shifts in LT etiologies underscore the success of public health interventions in reducing the burden of viral-related ESLD. Additionally, the findings highlight the need for ongoing research into the prevention, early diagnosis, and management of autoimmune liver diseases, MASH, and liver cancer. These findings provide critical insights for clinicians and policymakers to enhance liver disease management and allocate resources effectively.

Read More arrow

Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort

July 2025

CONCLUSIONS: Serum TSP2, alone or with clinical/biological variables, potently discriminates AF and ARM in patients with MASLD.

Read More arrow

Gut substrate trap of D-lactate from microbiota improves blood glucose and fatty liver disease in obese mice

July 2025

L-lactate participates in metabolism, including the Cori cycle, but less is known about D-lactate. We found that circulating D-lactate was higher in humans and mice with obesity. D-lactate increased hepatic glycogen, triglycerides, and blood glucose more than equimolar L-lactate in mice. Stable isotope analyses showed that D-lactate is metabolized in mice and in hepatocytes to pyruvate, TCA intermediates, lipids, and glucose. The gut microbiota is the main source of blood D-lactate. Colonization...

Read More arrow

Rapamycin ameliorates intrahepatic inflammation in MASLD by increasing macrophage fatty acid oxidation levels

July 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver disease and a serious threat to public health. Mammalian target of rapamycin (mTOR) plays an important role in the progression of MASLD and can be a potential therapeutic target. Our data show that rapamycin treatment can alleviate MASLD symptoms, including liver inflammation, steatosis and steatohepatitis, in the WD, CDHFD- or MCD-induced MASLD mouse model, but has no significant effect on hepatic fibrosis....

Read More arrow

Serum LEAP2 Levels Across the Spectrum of Metabolic Dysfunction-Associated Fatty Liver Disease: A Potential Noninvasive Biomarker for Severity Stratification

July 2025

CONCLUSION: Serum LEAP2 levels progressively increase with MAFLD severity and are independently associated with the disease. LEAP2 demonstrates potential as a noninvasive biomarker for assessing MAFLD severity, particularly in distinguishing MASH from healthy individuals. These findings warrant further investigation into LEAP2's pathophysiological role and therapeutic potential.

Read More arrow

Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated Angiogenesis

July 2025

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease linked to fibrosis and hepatocellular carcinoma (HCC). Gut-derived lipopolysaccharide (LPS) promotes hepatic inflammation, fibrosis, and angiogenesis through toll-like receptor 4 (TLR4) signaling. This study examined the effects of rifaximin, a non-absorbable, gut-targeted antibiotic, on MASH-related liver fibrosis and early hepatocarcinogenesis, with a focus on the LPS-epiregulin-IL-8-angiogenesis axis.MASH...

Read More arrow

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?

July 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are long-acting drugs that have gathered a lot of attention worldwide for their utility in the treatment landscape of type 2 diabetes mellitus and obesity. Their widespread global use has been accompanied by an additional observation related to a potential reduction in alcohol consumption. Preclinical studies in animal models, along with preliminary clinical findings, suggest that GLP-1 RAs may exert beneficial effects on alcohol use disorder...

Read More arrow